Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
CGP provides genomic context for HER2 status beyond the information provided by IHC and FISH, including detection of ERBB2 mutations and co-alterations that may suggest sensitivity/resistance to HER2-directed therapies, and is therefore crucial for guiding treatment choice and understanding individual patient response.
Authors
- Bob T. Li (ORCID: https://orcid.org/0000-0001-6661-8733)
- Justin Jee (ORCID: https://orcid.org/0000-0001-9783-0139)
- Alexa B. Schrock (ORCID: https://orcid.org/0000-0003-0106-9096)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Andreas M. Heilmann (ORCID: https://orcid.org/0000-0003-3906-8830)
- Rachel B. Keller-Evans (ORCID: https://orcid.org/0000-0001-6138-9257)
- Dazhi Liu (ORCID: https://orcid.org/0000-0003-3296-8203)
- Justin M. Allen (ORCID: https://orcid.org/0009-0004-9209-6886)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- GlobalFoundries (United States) (US)
- Kettering University (US)
- Foundation Medicine (United States)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0620
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- National Institutes of Health
- National Cancer Institute